Education
About Us
Working with TipRanks
Follow Us
Qualigen Therapeutics Inc (QLGN)
:QLGN
Total Valuation
Qualigen Therapeutics has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Qualigen Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Qualigen Therapeutics’s return on equity (ROE) is -2.30 and return on invested capital (ROIC) is -215.29%.
Return on Equity (ROE)-2.30
Return on Assets (ROA)-1.31
Return on Invested Capital (ROIC)-215.29%
Return on Capital Employed (ROCE)-2.15
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Qualigen Therapeutics is ―. Qualigen Therapeutics’s PEG ratio is -0.00041.
PE Ratio―
PS Ratio0.00
PB Ratio0.57
Price to Fair Value0.57
Price to FCF-0.24
Price to Operating Cash Flow1.88
PEG Ratio-0.00041
Income Statement
In the last 12 months, Qualigen Therapeutics had revenue of 0.00 and earned -6.16M in profits. Earnings per share was -17.28.
Revenue0.00
Gross Profit0.00
Operating Income-5.76M
Pretax Income-6.15M
Net Income-6.16M
EBITDA-5.24M
Earnings Per Share (EPS)-17.28
Cash Flow
In the last 12 months, operating cash flow was -7.10M and capital expenditures 0.00, giving a free cash flow of -7.10M billion.
Operating Cash Flow-7.10M
Free Cash Flow-7.10M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Qualigen Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change-39.45%
50-Day Moving Average3.62
200-Day Moving Average3.22
Relative Strength Index (RSI)39.96
Average Volume (3m)―
Important Dates
Qualigen Therapeutics upcoming earnings date is Aug 13, 2024, Before Open (Confirmed).
Last Earnings DateMay 10, 2024
Next Earnings DateAug 13, 2024
Ex-Dividend Date―
Financial Position
Qualigen Therapeutics as a current ratio of 2.33, with Debt / Equity ratio of 0.88%
Current Ratio2.33
Quick Ratio2.33
Debt to Market Cap0.00
Net Debt to EBITDA0.22
Interest Coverage Ratio-6.34
Taxes
In the past 12 months, Qualigen Therapeutics has paid 6.33K in taxes.
Income Tax6.33K
Effective Tax Rate>-0.01
Enterprise Valuation
Qualigen Therapeutics EV to EBITDA ratio is -0.07, with an EV/FCF ratio of -0.05.
EV to Sales0.00
EV to EBITDA-0.07
EV to Free Cash Flow-0.05
EV to Operating Cash Flow-0.05
Balance Sheet
Qualigen Therapeutics has $38.78M in cash and marketable securities with $3.24M in debt, giving a net cash position of $35.54M billion.
Cash & Marketable Securities$38.78M
Total Debt$3.24M
Net Cash$35.54M
Net Cash Per Share$10.00T>
Tangible Book Value Per Share$7.41
Margins
Gross margin is 49.20%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin49.20%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Qualigen Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast84.34%